Literature DB >> 24751106

The TAILOR study: to agree or to disagree?

Denis Moro-Sibilot1, David Perol2, Sylvie Chabaud2, Jacques Cadranel3, Clarisse Audigier Valette4, Maurice Perol5.   

Abstract

Keywords:  Chemotherapy; Lung cancer; Second line; Targeted therapy

Mesh：

Substances：

Year:  2014        PMID： 24751106     DOI： 10.1016/j.lungcan.2014.03.019

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  2 in total

1.  Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials.

Authors:  Raymond U Osarogiagbon; Federico Cappuzzo; Tudor Ciuleanu; Larry Leon; Barbara Klughammer
Journal:  Transl Lung Cancer Res       Date:  2015-08

2.  Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.

Authors:  Paul Germonpré; Tim Van den Wyngaert
Journal:  PLoS One       Date:  2019-04-11       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.